GSK plc has transferred 22 million treasury shares to JPMorgan Chase Bank to support its employee incentive plans, impacting shareholder engagement.
| Name | GSK plc |
|---|---|
| CIK | 0001131399 |
| Tickers | GSK, GLAXF |
| Exchanges | NYSE, OTC |
| Entity type | other |
| Category | Large accelerated filer |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 000000000 |
| LEI | — |
| Fiscal year end | — |
| State of incorporation | X0 United Kingdom |
| Phone | 44 20 8047 5000 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 0 |
| Insider transactions (owner) | 1 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
GSK plc has transferred 22 million treasury shares to JPMorgan Chase Bank to support its employee incentive plans, impacting shareholder engagement.
GSK's velzatinib gains Orphan Drug Designation in Japan for GIST treatment, accelerating clinical trials and enhancing its oncology portfolio.
GSK plc announces FDA approval of Nelkarmi for advanced ALK-positive lung cancer, enhancing its oncology portfolio and addressing patient needs.
GSK plc discloses a transaction involving shares acquired by Dr. Hal Barron, a Non-Executive Director, emphasizing transparency in executive dealings.
GSK's Bexsero booster vaccine for adolescents gets positive CHMP opinion, enhancing its market position in the pharmaceutical preparations sector.
GSK plc has acquired ordinary shares under its Share Reward Plan, reflecting its commitment to employee engagement and retention.
GSK plc has published provisional dividend dates for 2027, highlighting its commitment to shareholders and stability in the pharmaceutical sector.
GSK plc announces total voting rights for November 2026, totaling over 4 billion, reflecting its share capital structure.
GSK plc's Q3 results show a 15% increase in specialty medicines sales, reflecting strong performance and continued pipeline progress.
GSK plc announces positive phase III trial results for Ris-Rez in treating relapsed osteosarcoma, showing a 67% reduction in disease progression.
GSK plc's President, Maya Martinez-Davis, acquires shares, reflecting executive involvement in company performance. Details on the transaction provided.
GSK plc presents encouraging results for Mo-Rez, a new treatment for platinum-resistant ovarian cancer, showing a 62% response rate in phase I trials.
GSK plc announces a 76% complete response rate for Jemperli in a rectal cancer trial, marking a potential shift in treatment approaches.
GSK plc's Hibsago gains FDA approval for chronic hepatitis B, offering new hope for patients with significant cure rates over existing therapies.
GSK plc's Jemperli receives FDA approval as the first immunotherapy for advanced rectal cancer, offering new hope for patients.
GSK plc announces positive trial results for Ris-Rez, a new treatment for extensive-stage small cell lung cancer, showcasing its commitment to oncology advancements.
GSK plc executives acquire shares, indicating confidence in the company's future. This move reflects trends in the pharmaceutical preparations industry.
GSK plc CEO Luke Miels has increased his shareholdings, reflecting a commitment to leadership and aligning executive interests with shareholder value.
GSK plc CEO Luke Miels has acquired shares following a dividend reinvestment, signaling alignment with shareholder interests.
GSK plc CEO Luke Miels acquires ordinary shares after dividend reinvestment, signaling confidence in the company's future.
GSK plc appoints Wendy Becker as Non-Executive Director of Tesco PLC, effective November 1, 2026, emphasizing board diversity and governance.
GSK plc has announced the admission of ordinary shares to trading, enhancing shareholder value and reflecting trends in the pharmaceutical industry.
6860 filing rows loaded from submissions recent; extra archives: CIK0001131399-submissions-001.json (2002 filings, 2013-10-04 to 2022-08-14); CIK0001131399-submissions-002.json (2001 filings, 2007-09-13 to 2013-10-02); CIK0001131399-submissions-003.json (1856 filings, 2001-01-12 to 2007-09-11).
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | 6-K | TRANSFER OF TREASURY SHARES | 0001654954-26-010027 | 001-15170 | 261577352 | 34 | 22130 | |||
| 2026-11-19 | 6-K | VELZATINIB OBTAINS ODD IN JAPAN FOR GIST TREATMENT | 0001654954-26-009980 | 001-15170 | 261572320 | 34 | 43379 | |||
| 2026-11-18 | 6-K | FDA APPROVES NELKARMI FOR PRETREATED ALK+ NSCLC | 0001654954-26-009959 | 001-15170 | 261568010 | 34 | 47247 | |||
| 2026-11-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-009909 | 001-15170 | 261564412 | 34 | 98275 | |||
| 2026-11-13 | 6-K | BEXSERO BOOSTER RECEIVES POSITIVE CHMP OPINION | 0001654954-26-009743 | 001-15170 | 261548905 | 34 | 44404 | |||
| 2026-11-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-009712 | 001-15170 | 261544683 | 34 | 212934 | |||
| 2026-11-06 | 6-K | GSK PUBLISHES PROVISIONAL DIVIDEND DATES | 0001654954-26-009585 | 001-15170 | 261529897 | 34 | 27404 | |||
| 2026-11-05 | 13F-HR | xslForm13F_X02/primary_doc.xml | 0001999371-26-024635 | 028-26280 | 261527191 | 34 | 9917 | |||
| 2026-11-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-009362 | 001-15170 | 261510482 | 34 | 18710 | |||
| 2026-10-28 | 6-K | 3RD QUARTER RESULTS | 0001654954-26-009181 | 001-15170 | 261493689 | 34 | 1873920 | |||
| 2026-10-26 | 6-K | RIS-REZ POSITIVE PH 3 OSTEOSARCOMA DATA IN CHINA | 0001654954-26-009141 | 001-15170 | 261484801 | 34 | 45620 | |||
| 2026-10-26 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-009139 | 001-15170 | 261484775 | 34 | 34108 | |||
| 2026-10-26 | 6-K | JEMPERLI DATA SHOW 76% COMPLETE RESPONSE RATE | 0001654954-26-009130 | 001-15170 | 261483512 | 34 | 50352 | |||
| 2026-10-26 | 6-K | POSITIVE MO-REZ PHASE IB DATA IN OVARIAN CANCER | 0001654954-26-009127 | 001-15170 | 261483474 | 34 | 54321 | |||
| 2026-10-21 | 6-K | US FDA APPROVES HIBSAGO FOR CHRONIC HEPATITIS B | 0001654954-26-009062 | 001-15170 | 261474107 | 34 | 53545 | |||
| 2026-10-19 | 6-K | JEMPERLI APPROVED IN MSI-H/DMMR RECTAL CANCER | 0001654954-26-009036 | 001-15170 | 261468368 | 34 | 52310 | |||
| 2026-10-19 | 6-K | RIS-REZ POSITIVE EARLY DATA IN LUNG CANCER | 0001654954-26-009023 | 001-15170 | 261467505 | 34 | 49093 | |||
| 2026-10-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008959 | 001-15170 | 261461934 | 34 | 74756 | |||
| 2026-10-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008950 | 001-15170 | 261459003 | 34 | 265422 | |||
| 2026-10-13 | S-8 | S-8 | 0001193125-26-420025 | 333-299423 | 261455856 | 33 | 589512 | 1 | 1 | |
| 2026-10-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008921 | 001-15170 | 261455773 | 34 | 417513 | |||
| 2026-10-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008889 | 001-15170 | 261454469 | 34 | 537938 | |||
| 2026-10-08 | 6-K | WENDY BECKER CBE - NEW DIRECTORSHIP | 0001654954-26-008854 | 001-15170 | 261448924 | 34 | 17179 | |||
| 2026-10-06 | 6-K | ADMISSION TO TRADING | 0001654954-26-008813 | 001-15170 | 261442658 | 34 | 30198 | |||
| 2026-10-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-008733 | 001-15170 | 261429540 | 34 | 20499 | |||
| 2026-09-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008553 | 001-15170 | 261402967 | 34 | 35142 | |||
| 2026-09-22 | CERT | NYSE CERTIFICATION | 0000876661-26-000783 | 001-15170 | 261395677 | 34 | 159899 | |||
| 2026-09-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008503 | 001-15170 | 261395625 | 34 | 176795 | |||
| 2026-09-15 | 8-A12B | 8-A12B | 0001193125-26-391619 | 001-15170 | 261379938 | 34 | 383660 | |||
| 2026-09-15 | 6-K | 6-K | 0001193125-26-391597 | 001-15170 | 261379867 | 34 | 203672 | |||
| 2026-09-15 | 6-K | GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA | 0001654954-26-008359 | 001-15170 | 261379046 | 34 | 41998 | |||
| 2026-09-14 | 6-K | RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA | 0001654954-26-008321 | 001-15170 | 261375798 | 34 | 48655 | |||
| 2026-09-14 | 6-K | JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC | 0001654954-26-008318 | 001-15170 | 261375787 | 34 | 50022 | |||
| 2026-09-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008280 | 001-15170 | 261373049 | 34 | 214830 | |||
| 2026-09-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008255 | 001-15170 | 261370009 | 34 | 36277 | |||
| 2026-09-10 | 424B2 | 424B2 | 0001193125-26-387354 | 333-278205 | 261369760 | 33 | 758797 | 1 | 1 | |
| 2026-09-10 | 6-K | JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE | 0001654954-26-008234 | 001-15170 | 261369558 | 34 | 44948 | |||
| 2026-09-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008205 | 001-15170 | 261367129 | 34 | 51877 | |||
| 2026-09-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008202 | 001-15170 | 261367092 | 34 | 40856 | |||
| 2026-09-09 | FWP | FWP | 0001193125-26-385857 | 333-278205 | 261366600 | 34 | 33598 | |||
| 2026-09-08 | 424B2 | 424B2 | 0001193125-26-384490 | 333-278205 | 261363570 | 33 | 607528 | |||
| 2026-09-08 | 6-K | 6-K | 0001193125-26-384439 | 001-15170 | 261363474 | 34 | 2262969 | |||
| 2026-09-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-008044 | 001-15170 | 261349475 | 34 | 19937 | |||
| 2026-09-01 | 6-K | MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III | 0001654954-26-007998 | 001-15170 | 261348536 | 34 | 46570 | |||
| 2026-08-26 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-007877 | 001-15170 | 261318438 | 34 | 35203 | |||
| 2026-08-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-007810 | 001-15170 | 261307212 | 34 | 61721 | |||
| 2026-08-24 | 6-K | FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN | 0001654954-26-007800 | 001-15170 | 261306310 | 34 | 57712 | |||
| 2026-08-24 | 6-K | US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER | 0001654954-26-007798 | 001-15170 | 261306294 | 34 | 57701 | |||
| 2026-08-20 | 144 | xsl144X01/primary_doc.xml | 0001949846-26-000534 | 001-15170 | 261298084 | 33 | 7641 | |||
| 2026-08-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-007718 | 001-15170 | 261288939 | 34 | 95976 | |||
| 2026-08-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001193125-26-349401 | 005-84251 | 261274308 | 34 | 7385 | |||
| 2026-08-13 | 13F-HR | xslForm13F_X02/primary_doc.xml | 0001999371-26-017873 | 028-26280 | 261274109 | 34 | 9920 | |||
| 2026-08-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-007560 | 001-15170 | 261271286 | 34 | 195949 | |||
| 2026-08-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-007453 | 001-15170 | 261261376 | 34 | 34223 | |||
| 2026-08-03 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-007176 | 001-15170 | 261231158 | 34 | 20680 | |||
| 2026-07-30 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-007005 | 001-15170 | 261221625 | 34 | 35885 | |||
| 2026-07-28 | 6-K | NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE | 0001654954-26-006954 | 001-15170 | 261209987 | 34 | 37364 | |||
| 2026-07-28 | 6-K | HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ | 0001654954-26-006951 | 001-15170 | 261209921 | 34 | 43771 | |||
| 2026-07-28 | 6-K | 2ND QUARTER RESULTS | 0001654954-26-006949 | 001-15170 | 261209805 | 34 | 1941025 | |||
| 2026-07-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-006862 | 001-15170 | 261199629 | 34 | 34050 | |||
| 2026-07-24 | 6-K | ADMISSION TO TRADING | 0001654954-26-006854 | 001-15170 | 261199214 | 34 | 30188 | |||
| 2026-07-22 | 6-K | JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS | 0001654954-26-006789 | 001-15170 | 261192906 | 34 | 51703 | |||
| 2026-07-20 | 6-K | BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE | 0001654954-26-006735 | 001-15170 | 261185476 | 34 | 39751 | |||
| 2026-07-17 | 6-K | AUDIT TENDER CONCLUSION | 0001654954-26-006706 | 001-15170 | 261181852 | 34 | 19084 | |||
| 2026-07-17 | 6-K | CAMLIPIXANT PHASE III RESULTS UPDATE | 0001654954-26-006705 | 001-15170 | 261181825 | 34 | 36533 | |||
| 2026-07-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-006691 | 001-15170 | 261179088 | 34 | 239414 | |||
| 2026-07-15 | 6-K | GSK COMPLETES ACQUISITION OF NUVALENT, INC | 0001654954-26-006663 | 001-15170 | 261176106 | 34 | 38131 | |||
| 2026-07-15 | SC TO-T/A | SC TO-T/A | 0001193125-26-304122 | 24074 | ||||||
| 2026-07-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-006640 | 001-15170 | 261173107 | 34 | 570599 | |||
| 2026-07-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-006623 | 001-15170 | 261170499 | 34 | 434544 | |||
| 2026-07-13 | 6-K | POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER | 0001654954-26-006614 | 001-15170 | 261169919 | 34 | 51869 | |||
| 2026-07-10 | SC TO-T/A | SC TO-T/A | 0001193125-26-300322 | 23142 | ||||||
| 2026-07-10 | 6-K | HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ | 0001654954-26-006601 | 001-15170 | 261167007 | 34 | 42128 | |||
| 2026-07-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-006560 | 001-15170 | 261164658 | 34 | 34418 | |||
| 2026-07-09 | 6-K | DIRECTORATE CHANGE | 0001654954-26-006557 | 001-15170 | 261163967 | 34 | 31998 | |||
| 2026-07-07 | SC TO-T/A | SC TO-T/A | 0001193125-26-297562 | 26958 | ||||||
| 2026-07-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-006424 | 001-15170 | 261143092 | 34 | 18699 | |||
| 2026-06-29 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-006273 | 001-15170 | 261132317 | 34 | 48964 | |||
| 2026-06-29 | 6-K | HOLDING(S) IN COMPANY | 0001654954-26-006269 | 001-15170 | 261132292 | 34 | 66034 | |||
| 2026-06-26 | 6-K | HOLDING(S) IN COMPANY | 0001654954-26-006220 | 001-15170 | 261124603 | 34 | 61388 | |||
| 2026-06-24 | SC TO-T/A | SC TO-T/A | 0001193125-26-281024 | 61972 | ||||||
| 2026-06-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-006170 | 001-15170 | 261114194 | 34 | 35392 | |||
| 2026-06-24 | 6-K | GSK ANNOUNCES TENDER OFFER TO ACQUIRE NUVALENT | 0001654954-26-006168 | 001-15170 | 261114018 | 34 | 61313 | |||
| 2026-06-24 | SC TO-T | SC TO-T | 0001193125-26-280246 | 2485409 | 1 | 1 | ||||
| 2026-06-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-006116 | 001-15170 | 261109648 | 34 | 158462 | |||
| 2026-06-22 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-006106 | 001-15170 | 261105480 | 34 | 46622 | |||
| 2026-06-17 | 11-K | 11-K | 0001628280-26-043782 | 001-15170 | 261097253 | 34 | 3295340 | 1 | 1 | |
| 2026-06-17 | 11-K | 11-K | 0001628280-26-043773 | 001-15170 | 261097170 | 34 | 4517849 | 1 | 1 | |
| 2026-06-17 | 6-K | CUTI ORAL ANTIBIOTIC TEBIPENEM APPROVED BY US FDA | 0001654954-26-006036 | 001-15170 | 261097163 | 34 | 60037 | |||
| 2026-06-15 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-005975 | 001-15170 | 261089307 | 34 | 46867 | |||
| 2026-06-12 | 6-K | MOMELOTINIB ORPHAN DRUG DESIGNATIONS FOR VEXAS | 0001654954-26-005913 | 001-15170 | 261084870 | 34 | 51369 | |||
| 2026-06-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-005880 | 001-15170 | 261081786 | 34 | 203609 | |||
| 2026-06-10 | SC TO-C | SC TO-C | 0001193125-26-265991 | 649263 | ||||||
| 2026-06-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-005844 | 001-15170 | 261078578 | 34 | 34042 | |||
| 2026-06-09 | SC TO-C | SC TO-C | 0001193125-26-264048 | 10139241 | ||||||
| 2026-06-09 | 6-K | DR HAL BARRON - NEW DIRECTORSHIP | 0001654954-26-005819 | 001-15170 | 261075467 | 34 | 19669 | |||
| 2026-06-09 | SC TO-C | SC TO-C | 0001193125-26-262957 | 73550 | ||||||
| 2026-06-09 | 6-K | GSK ENTERS AGREEMENT TO ACQUIRE NUVALENT, INC. | 0001654954-26-005800 | 001-15170 | 261074523 | 34 | 64548 | |||
| 2026-06-08 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-005771 | 001-15170 | 261072675 | 34 | 47362 | |||
| 2026-06-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-005589 | 001-15170 | 261048005 | 34 | 19647 | |||
| 2026-06-01 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-005584 | 001-15170 | 261047807 | 34 | 44773 | |||
| 2026-05-28 | 6-K | POSITIVE PHASE 3 DATA FOR BEPIROVIRSEN | 0001654954-26-005453 | 001-15170 | 261028389 | 34 | 73910 | |||
| 2026-05-27 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-005405 | 001-15170 | 261022935 | 34 | 35493 | |||
| 2026-05-26 | SD | SPECIALIZED DISCLOSURE REPORT | 0001999371-26-011448 | 001-15170 | 261019922 | 34 | 19190 | |||
| 2026-05-26 | 6-K | ADMISSION TO TRADING | 0001654954-26-005339 | 001-15170 | 261016590 | 34 | 29297 | |||
| 2026-05-26 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-005335 | 001-15170 | 261016520 | 34 | 47306 | |||
| 2026-05-22 | 6-K | Q2 2026 RESULTS DATE CONFIRMED - 28 JULY 2026 | 0001654954-26-005250 | 001-15170 | 261010726 | 34 | 27497 | |||
| 2026-05-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-005164 | 001-15170 | 261002335 | 34 | 35862 | |||
| 2026-05-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-005163 | 001-15170 | 261002333 | 34 | 35862 | |||
| 2026-05-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-005102 | 001-15170 | 26996610 | 34 | 77621 | |||
| 2026-05-18 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-005052 | 001-15170 | 26991321 | 34 | 47631 | |||
| 2026-05-18 | 6-K | JAPAN MHLW APPROVES AREXVY FOR ADULTS 18-49 AIR | 0001654954-26-005024 | 001-15170 | 26990728 | 34 | 68432 | |||
| 2026-05-14 | 13F-HR | xslForm13F_X02/primary_doc.xml | 0001999371-26-010742 | 028-26280 | 26979943 | 34 | 9967 | |||
| 2026-05-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-004863 | 001-15170 | 26977088 | 34 | 215133 | |||
| 2026-05-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-004654 | 001-15170 | 26961494 | 34 | 34034 | |||
| 2026-05-11 | 6-K | COLLABORATION WITH CTTQ FOR BEPIROVIRSEN | 0001654954-26-004645 | 001-15170 | 26960764 | 34 | 46920 | |||
| 2026-05-11 | 6-K | GSK - FINAL TRANCHE OF SHARE BUYBACK PROGRAMME | 0001654954-26-004643 | 001-15170 | 26960748 | 34 | 35028 | |||
| 2026-05-06 | 6-K | RESULT OF AGM | 0001654954-26-004409 | 001-15170 | 26947506 | 34 | 109662 | |||
| 2026-05-06 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000315066-26-001214 | 005-84251 | 26946766 | 34 | 11217 | |||
| 2026-05-05 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-004342 | 001-15170 | 26941814 | 34 | 39047 | |||
| 2026-05-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-004251 | 001-15170 | 26930071 | 34 | 20095 | |||
| 2026-05-01 | 6-K | HOLDING(S) IN COMPANY | 0001654954-26-004250 | 001-15170 | 26929989 | 34 | 64322 | |||
| 2026-04-29 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-004056 | 001-15170 | 26912410 | 34 | 57981 | |||
| 2026-04-29 | 6-K | 1ST QUARTER RESULTS | 0001654954-26-004051 | 001-15170 | 26910654 | 34 | 1545662 | |||
| 2026-04-28 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-003992 | 001-15170 | 26904629 | 34 | 36800 | |||
| 2026-04-28 | 6-K | BEPIROVIRSEN PRIORITY REVIEW US FILING ACCEPTANCE | 0001654954-26-003977 | 001-15170 | 26903133 | 34 | 46153 | |||
| 2026-04-27 | 6-K | EFIMOSFERMIN GRANTED US/EU REGULATORY DESIGNATIONS | 0001654954-26-003947 | 001-15170 | 26896654 | 34 | 44329 | |||
| 2026-04-27 | 6-K | TESARO UPDATE ON ANAPTYSBIO INC. LITIGATION | 0001654954-26-003940 | 001-15170 | 26896451 | 34 | 32242 | |||
| 2026-04-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-003895 | 001-15170 | 26891416 | 34 | 34337 | |||
| 2026-04-23 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003814 | 001-15170 | 26885376 | 34 | 6628519 | |||
| 2026-04-22 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003778 | 001-15170 | 26881213 | 34 | 4076251 | |||
| 2026-04-21 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003750 | 001-15170 | 26876644 | 34 | 3737880 | |||
| 2026-04-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-003726 | 001-15170 | 26874278 | 34 | 35251 | |||
| 2026-04-20 | 6-K | BLENREP APPROVED IN CHINA FOR 2L+ MULTIPLE MYELOMA | 0001654954-26-003693 | 001-15170 | 26873308 | 34 | 63701 | |||
| 2026-04-20 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003688 | 001-15170 | 26873291 | 34 | 3929346 | |||
| 2026-04-17 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003629 | 001-15170 | 26869338 | 34 | 3321280 | |||
| 2026-04-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-003598 | 001-15170 | 26866490 | 34 | 507726 | |||
| 2026-04-16 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003565 | 001-15170 | 26865634 | 34 | 3740554 | |||
| 2026-04-15 | 6-K | GSK COMPLETES ACQUISITION OF 35PHARMA INC. | 0001654954-26-003518 | 001-15170 | 26862490 | 34 | 35889 | |||
| 2026-04-15 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003516 | 001-15170 | 26862447 | 34 | 3536037 | |||
| 2026-04-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-003483 | 001-15170 | 26859769 | 34 | 218294 | |||
| 2026-04-14 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003463 | 001-15170 | 26859125 | 34 | 4078906 | |||
| 2026-04-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-003439 | 001-15170 | 26856901 | 34 | 376156 | |||
| 2026-04-13 | 6-K | GSK PRESENTS POSITIVE DATA FOR BEHOLD 1 B7 H4 ADC | 0001654954-26-003422 | 001-15170 | 26856385 | 34 | 51567 | |||
| 2026-04-13 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003420 | 001-15170 | 26856366 | 34 | 4086896 | |||
| 2026-04-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-003401 | 001-15170 | 26853830 | 34 | 269379 | |||
| 2026-04-10 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003393 | 001-15170 | 26853120 | 34 | 3660575 | |||
| 2026-04-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-003371 | 001-15170 | 26850636 | 34 | 39377 | |||
| 2026-04-09 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003362 | 001-15170 | 26849758 | 34 | 4439501 | |||
| 2026-04-08 | 6-K | EXDENSUR APPROVED FOR CRSWNP IN CHINA | 0001654954-26-003334 | 001-15170 | 26846551 | 34 | 63731 | |||
| 2026-04-08 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003331 | 001-15170 | 26846546 | 34 | 4255537 | |||
| 2026-04-07 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003274 | 001-15170 | 26842998 | 34 | 3870883 | |||
| 2026-04-02 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003197 | 001-15170 | 26830636 | 34 | 4274306 | |||
| 2026-04-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-003166 | 001-15170 | 26826454 | 34 | 57538 | |||
| 2026-04-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-003162 | 001-15170 | 26826119 | 34 | 20674 | |||
| 2026-04-01 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-003122 | 001-15170 | 26824638 | 34 | 3704260 | |||
| 2026-04-01 | 6-K | VIIV COMPLETES CHANGES TO MINORITY SHAREHOLDING | 0001654954-26-003119 | 001-15170 | 26824605 | 34 | 37205 | |||
| 2026-03-31 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002995 | 001-15170 | 26816732 | 34 | 3984491 | |||
| 2026-03-30 | 6-K | BEPIROVIRSEN ACCEPTED FOR REVIEW IN CHINA | 0001654954-26-002919 | 001-15170 | 26809917 | 34 | 42261 | |||
| 2026-03-30 | 6-K | EXDENSUR APPROVED FOR SEVERE ASTHMA IN CHINA | 0001654954-26-002916 | 001-15170 | 26809884 | 34 | 61832 | |||
| 2026-03-30 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002914 | 001-15170 | 26809841 | 34 | 4519116 | |||
| 2026-03-27 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002851 | 001-15170 | 26801091 | 34 | 2298716 | |||
| 2026-03-27 | 6-K | BEPIROVIRSEN ACCEPTED FOR REVIEW BY THE EMA | 0001654954-26-002848 | 001-15170 | 26801084 | 34 | 42964 | |||
| 2026-03-26 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002780 | 001-15170 | 26794306 | 34 | 3170145 | |||
| 2026-03-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002744 | 001-15170 | 26790765 | 34 | 36440 | |||
| 2026-03-25 | 6-K | NOTICE OF AGM | 0001654954-26-002728 | 001-15170 | 26788700 | 34 | 22611 | |||
| 2026-03-25 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002709 | 001-15170 | 26788328 | 34 | 8812707 | |||
| 2026-03-24 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002641 | 001-15170 | 26784192 | 34 | 12118557 | |||
| 2026-03-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002600 | 001-15170 | 26780911 | 34 | 204094 | |||
| 2026-03-23 | 6-K | ADMISSION TO TRADING | 0001654954-26-002596 | 001-15170 | 26780634 | 34 | 31006 | |||
| 2026-03-23 | 6-K | GSK LUNG CANCER ADC GETS JAPAN ORPHAN DRUG STATUS | 0001654954-26-002580 | 001-15170 | 26779928 | 34 | 42222 | |||
| 2026-03-23 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002577 | 001-15170 | 26779921 | 34 | 8688352 | |||
| 2026-03-20 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002514 | 001-15170 | 26776085 | 34 | 10716140 | |||
| 2026-03-19 | 6-K | LYNAVOY (LINERIXIBAT) APPROVED BY US FDA | 0001654954-26-002482 | 001-15170 | 26772718 | 34 | 47987 | |||
| 2026-03-19 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002466 | 001-15170 | 26772396 | 34 | 10556594 | |||
| 2026-03-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002367 | 001-15170 | 26767477 | 34 | 37276 | |||
| 2026-03-18 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002356 | 001-15170 | 26765765 | 34 | 7993916 | |||
| 2026-03-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002324 | 001-15170 | 26760938 | 34 | 36913 | |||
| 2026-03-17 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002311 | 001-15170 | 26759078 | 34 | 7079938 | |||
| 2026-03-16 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002266 | 001-15170 | 26754571 | 34 | 4190327 | |||
| 2026-03-13 | 6-K | US FDA APPROVES AREXVY FOR ADULTS 18-49 AIR | 0001654954-26-002214 | 001-15170 | 26750141 | 34 | 54834 | |||
| 2026-03-13 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002208 | 001-15170 | 26750059 | 34 | 10129686 | |||
| 2026-03-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002183 | 001-15170 | 26746789 | 34 | 232780 | |||
| 2026-03-12 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002166 | 001-15170 | 26745755 | 34 | 6888084 | |||
| 2026-03-11 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002120 | 001-15170 | 26741556 | 34 | 4625736 | |||
| 2026-03-10 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002076 | 001-15170 | 26737254 | 34 | 4548827 | |||
| 2026-03-09 | 6-K | BOARD COMMITTEE CHANGE | 0001654954-26-002019 | 001-15170 | 26733841 | 34 | 18236 | |||
| 2026-03-09 | 6-K | GSK AND ALFASIGMA AGREE GLOBAL LINERIXIBAT RIGHTS | 0001654954-26-002008 | 001-15170 | 26733282 | 34 | 43024 | |||
| 2026-03-09 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002005 | 001-15170 | 26733252 | 34 | 6387463 | |||
| 2026-03-06 | 6-K | FILING OF GSK PLC 2025 ANNUAL REPORT ON FORM 20-F | 0001654954-26-001975 | 001-15170 | 26728970 | 34 | 22685 | |||
| 2026-03-06 | IRANNOTICE | IRANNOTICE | 0001131399-26-000006 | 001-15170 | 26728716 | 34 | 373734 | |||
| 2026-03-06 | 20-F | 20-F | 0001131399-26-000004 | 001-15170 | 26728707 | 34 | 101116598 | 1 | 1 | |
| 2026-03-06 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001950 | 001-15170 | 26728440 | 34 | 9795016 | |||
| 2026-03-05 | 6-K | GSK PUBLISHES ANNUAL REPORT 2025 | 0001654954-26-001917 | 001-15170 | 26724518 | 34 | 21958 | |||
| 2026-03-05 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001907 | 001-15170 | 26724445 | 34 | 7224083 | |||
| 2026-03-04 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001860 | 001-15170 | 26719710 | 34 | 34394 | |||
| 2026-03-04 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001852 | 001-15170 | 26718721 | 34 | 9384427 | |||
| 2026-03-03 | 6-K | GSK COMPLETES ACQUISITION OF RAPT THERAPEUTICS | 0001654954-26-001801 | 001-15170 | 26711856 | 34 | 38317 | |||
| 2026-03-03 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001790 | 001-15170 | 26710979 | 34 | 6152119 | |||
| 2026-03-03 | SC TO-T/A | SC TO-T/A | 0001193125-26-086527 | 22680 | ||||||
| 2026-03-02 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001756 | 001-15170 | 26706665 | 34 | 5311289 | |||
| 2026-03-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-001733 | 001-15170 | 26705623 | 34 | 20444 | |||
| 2026-02-27 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001650 | 001-15170 | 26695957 | 34 | 33944 | |||
| 2026-02-27 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001625 | 001-15170 | 26692582 | 34 | 7436356 | |||
| 2026-02-26 | 6-K | LINERIXIBAT ACCEPTED FOR PRIORITY REVIEW IN CHINA | 0001654954-26-001580 | 001-15170 | 26681615 | 34 | 40958 | |||
| 2026-02-26 | 6-K | BEPIROVIRSEN ACCEPTED FOR JAPAN REGULATORY REVIEW | 0001654954-26-001578 | 001-15170 | 26681605 | 34 | 46066 | |||
| 2026-02-26 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001575 | 001-15170 | 26681579 | 34 | 5417869 | |||
| 2026-02-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001551 | 001-15170 | 26676466 | 34 | 33825 | |||
| 2026-02-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001547 | 001-15170 | 26675658 | 34 | 34242 | |||
| 2026-02-25 | 6-K | GSK ENTERS AGREEMENT TO ACQUIRE 35PHARMA | 0001654954-26-001533 | 001-15170 | 26675231 | 34 | 41706 | |||
| 2026-02-25 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001531 | 001-15170 | 26675196 | 34 | 5469685 | |||
| 2026-02-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001495 | 001-15170 | 26668569 | 34 | 53112 | |||
| 2026-02-24 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001477 | 001-15170 | 26667388 | 34 | 5648178 | |||
| 2026-02-24 | SC TO-T/A | SC TO-T/A | 0001193125-26-065083 | 24318 | ||||||
| 2026-02-23 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001438 | 001-15170 | 26661971 | 34 | 5492420 | |||
| 2026-02-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001425 | 001-15170 | 26657423 | 34 | 35954 | |||
| 2026-02-20 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001411 | 001-15170 | 26656631 | 34 | 5822887 | |||
| 2026-02-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001380 | 001-15170 | 26652650 | 34 | 36504 | |||
| 2026-02-19 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001372 | 001-15170 | 26651435 | 34 | 5464062 | |||
| 2026-02-18 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001330 | 001-15170 | 26645365 | 34 | 5451186 | |||
| 2026-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001297 | 001-15170 | 26638432 | 34 | 55900 | |||
| 2026-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001295 | 001-15170 | 26638379 | 34 | 625679 | |||
| 2026-02-17 | 6-K | GSK - FOURTH TRANCHE OF SHARE BUYBACK PROGRAMME | 0001654954-26-001288 | 001-15170 | 26637617 | 34 | 33467 | |||
| 2026-02-17 | 6-K | EXDENSUR APPROVED BY THE EUROPEAN COMMISSION | 0001654954-26-001276 | 001-15170 | 26636819 | 34 | 64313 | |||
| 2026-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001267 | 001-15170 | 26636536 | 34 | 343746 | |||
| 2026-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001265 | 001-15170 | 26636444 | 34 | 200907 | |||
| 2026-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001262 | 001-15170 | 26636362 | 34 | 55929 | |||
| 2026-02-12 | 13F-HR | xslForm13F_X02/primary_doc.xml | 0001999371-26-003198 | 028-26280 | 26626707 | 34 | 10885 | |||
| 2026-02-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001125 | 001-15170 | 26619644 | 34 | 236589 | |||
| 2026-02-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001123 | 001-15170 | 26619562 | 34 | 388576 | |||
| 2026-02-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001116 | 001-15170 | 26619296 | 34 | 76869 | |||
| 2026-02-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001113 | 001-15170 | 26619257 | 34 | 261053 | |||
| 2026-02-10 | 6-K | CHINA CDE ACCEPTS AREXVY ADULTS 60+ APPLICATION | 0001654954-26-001068 | 001-15170 | 26614460 | 34 | 48289 | |||
| 2026-02-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001035 | 001-15170 | 26610253 | 34 | 36669 | |||
| 2026-02-06 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000976 | 001-15170 | 26605530 | 34 | 36778 | |||
| 2026-02-06 | 6-K | NUCALA COPD APPROVED BY THE EUROPEAN COMMISSION | 0001654954-26-000970 | 001-15170 | 26605371 | 34 | 53423 | |||
| 2026-02-05 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000949 | 001-15170 | 26602155 | 34 | 57895 | |||
| 2026-02-04 | 6-K | FINAL RESULTS | 0001654954-26-000892 | 001-15170 | 26596518 | 34 | 2409014 | |||
| 2026-02-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-000829 | 001-15170 | 26586912 | 34 | 19235 | |||
| 2026-02-02 | SC TO-T | SC TO-T | 0001193125-26-032610 | 1323120 | 1 | 1 | ||||
| 2026-01-26 | 6-K | EUROPEAN COMMISSION APPROVES AREXVY FOR ADULTS 18+ | 0001654954-26-000581 | 001-15170 | 26558643 | 34 | 44119 | |||
| 2026-01-20 | SC TO-C | SC TO-C | 0001193125-26-016553 | 3961310 | ||||||
| 2026-01-20 | SC TO-C | SC TO-C | 0001193125-26-016042 | 70771 | ||||||
| 2026-01-20 | 6-K | GSK TO ACQUIRE RAPT THERAPEUTICS | 0001654954-26-000470 | 001-15170 | 26541142 | 34 | 55659 | |||
| 2026-01-20 | 6-K | AGREEMENT ON CHANGES TO VIIV MINORITY SHAREHOLDING | 0001654954-26-000468 | 001-15170 | 26541140 | 34 | 42632 | |||
| 2026-01-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000417 | 001-15170 | 26538522 | 34 | 118987 | |||
| 2026-01-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000375 | 001-15170 | 26535168 | 34 | 56169 | |||
| 2026-01-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000324 | 001-15170 | 26529409 | 34 | 1067598 | |||
| 2026-01-07 | 6-K | EC APPROVAL OF SHINGRIX PFS | 0001654954-26-000138 | 001-15170 | 26513962 | 34 | 49065 | |||
| 2026-01-07 | 6-K | POSITIVE PHASE 3 DATA FOR GSK'S BEPIROVIRSEN | 0001654954-26-000136 | 001-15170 | 26513931 | 34 | 44902 | |||
| 2026-01-06 | 6-K | EXDENSUR APPROVED IN JAPAN | 0001654954-26-000107 | 001-15170 | 26509381 | 34 | 77832 | |||
| 2026-01-05 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-000071 | 001-15170 | 26504872 | 34 | 52552 | |||
| 2026-01-05 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-000061 | 001-15170 | 26504410 | 34 | 20037 | |||
| 2026-01-05 | 6-K | NUCALA FOR ADULTS WITH COPD APPROVED IN CHINA | 0001654954-26-000056 | 001-15170 | 26503836 | 34 | 50659 | |||
| 2025-12-23 | 6-K | GSK TO LOWER DRUG PRICES AND EXPAND ACCESS IN US | 0001654954-25-014268 | 001-15170 | 251594697 | 34 | 33883 | |||
| 2025-12-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-014212 | 001-15170 | 251591051 | 34 | 162411 | |||
| 2025-12-22 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-014156 | 001-15170 | 251589354 | 34 | 3651634 | |||
| 2025-12-19 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-014129 | 001-15170 | 251585018 | 34 | 3171865 | |||
| 2025-12-18 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-014074 | 001-15170 | 251581206 | 34 | 3980612 | |||
| 2025-12-17 | 6-K | EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDA | 0001654954-25-014033 | 001-15170 | 251577242 | 34 | 59592 | |||
| 2025-12-17 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-014027 | 001-15170 | 251577205 | 34 | 3568480 | |||
| 2025-12-16 | 6-K | EXDENSUR (DEPEMOKIMAB) UK MHRA APPROVAL | 0001654954-25-013981 | 001-15170 | 251573483 | 34 | 60510 | |||
| 2025-12-16 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013979 | 001-15170 | 251573385 | 34 | 3601750 | |||
| 2025-12-15 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | 0001999371-25-020336 | 001-37627 | 251572044 | 34 | 5728 | |||
| 2025-12-15 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013922 | 001-15170 | 251569973 | 34 | 3201099 | |||
| 2025-12-12 | 6-K | DEPEMOKIMAB RECEIVES POSITIVE CHMP OPINION | 0001654954-25-013890 | 001-15170 | 251566857 | 34 | 54300 | |||
| 2025-12-12 | 6-K | NUCALA RECEIVES POSITIVE CHMP OPINION FOR COPD | 0001654954-25-013887 | 001-15170 | 251566824 | 34 | 48412 | |||
| 2025-12-12 | 6-K | POSITIVE CHMP OPINION ON AREXVY FOR ALL ADULTS 18+ | 0001654954-25-013882 | 001-15170 | 251566696 | 34 | 46336 | |||
| 2025-12-12 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013879 | 001-15170 | 251566653 | 34 | 3261711 | |||
| 2025-12-11 | 6-K | BLUJEPA APPROVED IN US FOR GONORRHOEA INDICATION | 0001654954-25-013845 | 001-15170 | 251564404 | 34 | 51677 | |||
| 2025-12-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-013834 | 001-15170 | 251564104 | 34 | 193862 | |||
| 2025-12-11 | 6-K | BLOCK LISTING APPLICATION | 0001654954-25-013825 | 001-15170 | 251563525 | 34 | 18854 | |||
| 2025-12-11 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013823 | 001-15170 | 251563520 | 34 | 3310676 | |||
| 2025-12-10 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013792 | 001-15170 | 251560804 | 34 | 3494743 | |||
| 2025-12-10 | 6-K | GSK'227 US FDA ORPHAN DRUG DESIGNATION IN SCLC | 0001654954-25-013788 | 001-15170 | 251560767 | 34 | 39554 | |||
| 2025-12-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-013777 | 001-15170 | 251558256 | 34 | 35541 | |||
| 2025-12-09 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013768 | 001-15170 | 251557566 | 34 | 3370958 | |||
| 2025-12-08 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013741 | 001-15170 | 251554643 | 34 | 3365746 | |||
| 2025-12-05 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001999371-25-019650 | 31897 | ||||||
| 2025-12-05 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013692 | 001-15170 | 251551184 | 34 | 3513396 | |||
| 2025-12-04 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013661 | 001-15170 | 251548269 | 34 | 3024070 | |||
| 2025-12-03 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013632 | 001-15170 | 251545093 | 34 | 2675302 | |||
| 2025-12-02 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013604 | 001-15170 | 251541607 | 34 | 2225715 | |||
| 2025-12-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-013579 | 001-15170 | 251538547 | 34 | 72246 | |||
| 2025-12-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-013575 | 001-15170 | 251538451 | 34 | 19791 | |||
| 2025-12-01 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013521 | 001-15170 | 251537100 | 34 | 2925870 | |||
| 2025-11-28 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013497 | 001-15170 | 251533610 | 34 | 3057655 | |||
| 2025-11-28 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013468 | 001-15170 | 251532313 | 34 | 2168532 | |||
| 2025-11-26 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013446 | 001-15170 | 251523771 | 34 | 2418880 | |||
| 2025-11-25 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013418 | 001-15170 | 251514986 | 34 | 2223867 | |||
| 2025-11-24 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013399 | 001-15170 | 251509536 | 34 | 2325652 | |||
| 2025-11-21 | 6-K | INITIATION OF LITIGATION AGAINST ANAPTYSBIO INC | 0001654954-25-013351 | 001-15170 | 251504692 | 34 | 29120 | |||
| 2025-11-21 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013348 | 001-15170 | 251504600 | 34 | 4461435 | |||
| 2025-11-20 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013320 | 001-15170 | 251501190 | 34 | 3029427 | |||
| 2025-11-19 | 6-K | TRANSFER OF TREASURY SHARES | 0001654954-25-013250 | 001-15170 | 251496708 | 34 | 22295 | |||
| 2025-11-19 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013248 | 001-15170 | 251496689 | 34 | 2906108 | |||
| 2025-11-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-013187 | 001-15170 | 251493295 | 34 | 78109 | |||
| 2025-11-18 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013178 | 001-15170 | 251492900 | 34 | 2127607 | |||
| 2025-11-17 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013117 | 001-15170 | 251489232 | 34 | 2101535 | |||
| 2025-11-14 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-013014 | 001-15170 | 251481036 | 34 | 1942282 | |||
| 2025-11-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-012969 | 001-15170 | 251476602 | 34 | 194973 | |||
| 2025-11-13 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012955 | 001-15170 | 251475280 | 34 | 1841199 | |||
| 2025-11-12 | 6-K | BLOCK LISTING INTERIM REVIEW | 0001654954-25-012888 | 001-15170 | 251471371 | 34 | 45460 | |||
| 2025-11-12 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012845 | 001-15170 | 251470301 | 34 | 1619795 | |||
| 2025-11-12 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012792 | 001-15170 | 251468220 | 34 | 2047200 | |||
| 2025-11-10 | 6-K | GSK PUBLISHES PROVISIONAL DIVIDEND DATES | 0001654954-25-012745 | 001-15170 | 251465027 | 34 | 28770 | |||
| 2025-11-10 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012720 | 001-15170 | 251464303 | 34 | 1871577 | |||
| 2025-11-07 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012679 | 001-15170 | 251460285 | 34 | 2412336 | |||
| 2025-11-06 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012632 | 001-15170 | 251456228 | 34 | 1880016 | |||
| 2025-11-05 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012587 | 001-15170 | 251451615 | 34 | 1276405 | |||
| 2025-11-04 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012543 | 001-15170 | 251446426 | 34 | 2265434 | |||
| 2025-11-03 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-012505 | 001-15170 | 251443266 | 34 | 16649 | |||
| 2025-11-03 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012444 | 001-15170 | 251442020 | 34 | 2071432 | |||
| 2025-10-31 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012388 | 001-15170 | 251437936 | 34 | 1449907 | |||
| 2025-10-30 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-012360 | 001-15170 | 251433467 | 34 | 49181 | |||
| 2025-10-30 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012344 | 001-15170 | 251432333 | 34 | 1264517 | |||
| 2025-10-29 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012308 | 001-15170 | 251428276 | 34 | 2157054 | |||
| 2025-10-29 | 6-K | 3RD QUARTER RESULTS | 0001654954-25-012307 | 001-15170 | 251428198 | 34 | 2269344 | |||
| 2025-10-28 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012261 | 001-15170 | 251421458 | 34 | 1386144 | |||
| 2025-10-28 | 6-K | GSK ADC GETS ORPHAN DRUG DESIGNATION IN THE EU | 0001654954-25-012259 | 001-15170 | 251421331 | 34 | 37900 | |||
| 2025-10-27 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012225 | 001-15170 | 251417637 | 34 | 4438700 | |||
| 2025-10-24 | 6-K | BLENREP APPROVED BY US FDA IN MULTIPLE MYELOMA | 0001654954-25-012176 | 001-15170 | 251414461 | 34 | 69450 | |||
| 2025-10-24 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012159 | 001-15170 | 251414223 | 34 | 2803658 | |||
| 2025-10-23 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012082 | 001-15170 | 251411408 | 34 | 2042180 | |||
| 2025-10-22 | 6-K | POSITIVE DATA FOR LOW CARBON VERSION VENTOLIN MDI | 0001654954-25-012045 | 001-15170 | 251408712 | 34 | 39984 | |||
| 2025-10-22 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-012042 | 001-15170 | 251408653 | 34 | 1809296 | |||
| 2025-10-22 | 6-K | LATOZINEMAB DATA READ OUT | 0001654954-25-012035 | 001-15170 | 251408582 | 34 | 32032 | |||
| 2025-10-21 | 6-K | POSITIVE CHMP OPINION FOR GSK ON SHINGRIX PFS | 0001654954-25-011999 | 001-15170 | 251405380 | 34 | 49706 | |||
| 2025-10-21 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011992 | 001-15170 | 251405325 | 34 | 1699181 | |||
| 2025-10-21 | 6-K | GSK SHARE POSITIVE PH3 DATA ON TEBIPENEM HBR | 0001654954-25-011990 | 001-15170 | 251405313 | 34 | 58296 | |||
| 2025-10-20 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011945 | 001-15170 | 251402286 | 34 | 4977889 | |||
| 2025-10-17 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011905 | 001-15170 | 251398996 | 34 | 3754629 | |||
| 2025-10-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-011875 | 001-15170 | 251397008 | 34 | 69872 | |||
| 2025-10-16 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011846 | 001-15170 | 251396393 | 34 | 4675724 | |||
| 2025-10-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-011805 | 001-15170 | 251394093 | 34 | 322690 | |||
| 2025-10-15 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011786 | 001-15170 | 251393351 | 34 | 3400184 | |||
| 2025-10-14 | 6-K | GSK RECEIVES EXPANDED SHINGRIX APPROVAL IN CHINA | 0001654954-25-011717 | 001-15170 | 251389872 | 34 | 51136 | |||
| 2025-10-14 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011710 | 001-15170 | 251389647 | 34 | 2350087 | |||
| 2025-10-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-011702 | 001-15170 | 251389578 | 34 | 614176 | |||
| 2025-10-14 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011685 | 001-15170 | 251389176 | 34 | 2541574 | |||
| 2025-10-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-011651 | 001-15170 | 251386850 | 34 | 212023 | |||
| 2025-10-10 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011629 | 001-15170 | 251386220 | 34 | 1808364 | |||
| 2025-10-09 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011584 | 001-15170 | 251383620 | 34 | 2975970 | |||
| 2025-10-08 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011559 | 001-15170 | 251381195 | 34 | 3608518 | |||
| 2025-10-07 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011522 | 001-15170 | 251378202 | 34 | 4606939 | |||
| 2025-10-06 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011459 | 001-15170 | 251375593 | 34 | 4289762 | |||
| 2025-10-03 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011415 | 001-15170 | 251372036 | 34 | 4263431 | |||
| 2025-10-02 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011359 | 001-15170 | 251367003 | 34 | 4155217 | |||
| 2025-10-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-011307 | 001-15170 | 251362872 | 34 | 16884 | |||
| 2025-10-01 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-011296 | 001-15170 | 251362596 | 34 | 2188674 | |||
| 2025-09-30 | 6-K | GSK - THIRD TRANCHE OF SHARE BUYBACK PROGRAMME | 0001654954-25-011211 | 001-15170 | 251358185 | 34 | 31827 | |||
| 2025-09-29 | 6-K | GSK APPOINTS CEO DESIGNATE | 0001654954-25-011173 | 001-15170 | 251352052 | 34 | 51310 | |||
| 2025-09-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-010981 | 001-15170 | 251329260 | 34 | 164927 | |||
| 2025-09-19 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010923 | 001-15170 | 251324864 | 34 | 407066 | |||
| 2025-09-18 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010888 | 001-15170 | 251321767 | 34 | 3934641 | |||
| 2025-09-17 | 6-K | GSK US INVESTMENT ANNOUNCEMENT | 0001654954-25-010843 | 001-15170 | 251318766 | 34 | 34342 | |||
| 2025-09-17 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010835 | 001-15170 | 251318754 | 34 | 2505715 | |||
| 2025-09-16 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010794 | 001-15170 | 251316017 | 34 | 9441445 | |||
| 2025-09-15 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010739 | 001-15170 | 251313327 | 34 | 4789129 | |||
| 2025-09-12 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010672 | 001-15170 | 251309994 | 34 | 4671918 | |||
| 2025-09-11 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010634 | 001-15170 | 251307223 | 34 | 2308296 | |||
| 2025-09-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-010599 | 001-15170 | 251305140 | 34 | 199662 | |||
| 2025-09-10 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010565 | 001-15170 | 251304580 | 34 | 1455219 | |||
| 2025-09-09 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010505 | 001-15170 | 251301670 | 34 | 8031449 | |||
| 2025-09-08 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010455 | 001-15170 | 251298549 | 34 | 6283960 | |||
| 2025-09-05 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010429 | 001-15170 | 251294997 | 34 | 2620616 | |||
| 2025-09-04 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-010402 | 001-15170 | 251292353 | 34 | 32971 | |||
| 2025-09-04 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010384 | 001-15170 | 251291867 | 34 | 5562413 | |||
| 2025-09-03 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010336 | 001-15170 | 251287712 | 34 | 2512357 | |||
| 2025-09-02 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010285 | 001-15170 | 251283363 | 34 | 5770654 | |||
| 2025-09-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-010263 | 001-15170 | 251283104 | 34 | 16408 | |||
| 2025-09-02 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010241 | 001-15170 | 251282901 | 34 | 7105126 | |||
| 2025-08-29 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010165 | 001-15170 | 251275860 | 34 | 4909272 | |||
| 2025-08-28 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010110 | 001-15170 | 251267383 | 34 | 3547721 | |||
| 2025-08-27 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-010072 | 001-15170 | 251259812 | 34 | 2612860 | |||
| 2025-08-26 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-009996 | 001-15170 | 251252628 | 34 | 5366169 | |||
| 2025-08-22 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-009943 | 001-15170 | 251242534 | 34 | 8295349 | |||
| 2025-08-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-009886 | 001-15170 | 251239151 | 34 | 34230 | |||
| 2025-08-21 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-009874 | 001-15170 | 251238318 | 34 | 5001768 | |||
| 2025-08-20 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-009835 | 001-15170 | 251233763 | 34 | 6067125 | |||
| 2025-08-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-009804 | 001-15170 | 251230147 | 34 | 75628 | |||
| 2025-08-19 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-009782 | 001-15170 | 251229586 | 34 | 4382563 | |||
| 2025-08-18 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-009735 | 001-15170 | 251226221 | 34 | 2227064 | |||
| 2025-08-15 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-009682 | 001-15170 | 251222375 | 34 | 5675675 | |||
| 2025-08-14 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-009525 | 001-15170 | 251213965 | 34 | 1066515 | |||
| 2025-08-13 | SCHEDULE 13D | xslSCHEDULE_13D_X01/primary_doc.xml | 0001999371-25-011273 | 34262 | ||||||
| 2025-08-13 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-009467 | 001-15170 | 251208791 | 34 | 4354867 | |||
| 2025-08-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-009404 | 001-15170 | 251205567 | 34 | 197783 | |||
| 2025-08-12 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-009371 | 001-15170 | 251203901 | 34 | 5683172 | |||
| 2025-08-11 | 6-K | FDA TO REVIEW GONORRHEA INDICATION FOR GEPOTIDACIN | 0001654954-25-009314 | 001-15170 | 251200113 | 34 | 49154 | |||
| 2025-08-11 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-009310 | 001-15170 | 251200064 | 34 | 5898686 | |||
| 2025-08-08 | 6-K | CUREVAC/BIONTECH MRNA PATENT LITIGATION SETTLEMENT | 0001654954-25-009240 | 001-15170 | 251196133 | 34 | 32942 | |||
| 2025-08-08 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-009238 | 001-15170 | 251196130 | 34 | 7488943 | |||
| 2025-08-07 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-009167 | 001-15170 | 251191676 | 34 | 8475669 | |||
| 2025-08-06 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-009091 | 001-15170 | 251187342 | 34 | 7409984 | |||
| 2025-08-05 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-008956 | 001-15170 | 251182789 | 34 | 5221364 | |||
| 2025-08-04 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-008890 | 001-15170 | 251177928 | 34 | 10345128 | |||
| 2025-08-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-008811 | 001-15170 | 251175184 | 34 | 16590 | |||
| 2025-08-01 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-008795 | 001-15170 | 251174512 | 34 | 37686 | |||
| 2025-07-31 | 6-K | TRANSACTION IN OWN SHARES | 0001654954-25-008684 | 001-15170 | 251169548 | 34 | 5122158 |
One latest value per concept from companyfacts (432 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 4.32B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ffd | NetFeeAmt | NetFeeAmt | USD | 261,614.44 | 2026-10-13 | S-8 | 2026-10-13 | 0001193125-26-420025 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 261,614.44 | 2026-10-13 | S-8 | 2026-10-13 | 0001193125-26-420025 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 3.01B | 2026-10-13 | S-8 | 2026-10-13 | 0001193125-26-420025 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-10-13 | S-8 | 2026-10-13 | 0001193125-26-420025 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 0 | 2026-06-22 | SC TO-T | 2026-06-24 | 0001193125-26-280246 | |||
| ffd | TtlTxValtn | TtlTxValtn | USD | 10.63B | 2026-06-22 | SC TO-T | 2026-06-24 | 0001193125-26-280246 | |||
| ifrs-full | Accruals | Accruals | GBP | 6.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | AccrualsAndDeferredIncome | AccrualsAndDeferredIncome | GBP | 104.00M | 2017-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 | |
| ifrs-full | AccruedIncome | AccruedIncome | GBP | 13.00M | 2020-12-31 | 2020 | FY | 20-F | 2021-03-12 | 0001193125-21-079417 | |
| ifrs-full | AccruedIncomeOtherThanContractAssets | AccruedIncomeOtherThanContractAssets | GBP | 13.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | AcquisitiondateFairValueOfTotalConsiderationTransferred | AcquisitiondateFairValueOfTotalConsiderationTransferred | GBP | 2.01B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | AcquisitionsThroughBusinessCombinationsOtherProvisions | AcquisitionsThroughBusinessCombinationsOtherProvisions | GBP | 23.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AcquisitionsThroughBusinessCombinationsRightofuseAssets | AcquisitionsThroughBusinessCombinationsRightofuseAssets | GBP | 1.00M | 2023-01-01 | 2023-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | ActuarialAssumptionOfDiscountRates | ActuarialAssumptionOfDiscountRates | pure | 0.07 | 2017-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 | |
| ifrs-full | ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset | ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset | GBP | -62.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset | ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset | GBP | 211.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset | ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset | GBP | -99.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdditionalProvisionsOtherProvisions | AdditionalProvisionsOtherProvisions | GBP | 840.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdditionalRecognitionGoodwill | AdditionalRecognitionGoodwill | GBP | 1.13B | 2022-01-01 | 2022-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 |
| ifrs-full | AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets | AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets | GBP | 181.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdditionsToRightofuseAssets | AdditionsToRightofuseAssets | GBP | 215.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 |
| ifrs-full | AdjustedWeightedAverageShares | AdjustedWeightedAverageShares | shares | 4.12B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForAmortisationExpense | AdjustmentsForAmortisationExpense | GBP | 1.26B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForCurrentTaxOfPriorPeriod | AdjustmentsForCurrentTaxOfPriorPeriod | GBP | -49.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForDecreaseIncreaseInInventories | AdjustmentsForDecreaseIncreaseInInventories | GBP | -140.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables | AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables | GBP | -484.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForDecreaseIncreaseInTradeAccountReceivable | AdjustmentsForDecreaseIncreaseInTradeAccountReceivable | GBP | -613.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForDepreciationExpense | AdjustmentsForDepreciationExpense | GBP | 1.06B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForFairValueGainsLosses | AdjustmentsForFairValueGainsLosses | GBP | 45.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForFinanceIncomeCost | AdjustmentsForFinanceIncomeCost | GBP | -532.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates | AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates | GBP | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForIncomeTaxExpense | AdjustmentsForIncomeTaxExpense | GBP | 1.11B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities | AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities | GBP | -1.14B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForIncreaseDecreaseInOtherOperatingPayables | AdjustmentsForIncreaseDecreaseInOtherOperatingPayables | GBP | 343.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForIncreaseDecreaseInTradeAccountPayable | AdjustmentsForIncreaseDecreaseInTradeAccountPayable | GBP | 131.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForReconcileProfitLoss | AdjustmentsForReconcileProfitLoss | GBP | 2.65B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdjustmentsForSharebasedPayments | AdjustmentsForSharebasedPayments | GBP | 374.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AdvertisingExpense | AdvertisingExpense | GBP | 738.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AmortisationIntangibleAssetsOtherThanGoodwill | AmortisationIntangibleAssetsOtherThanGoodwill | GBP | 1.26B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ApplicableTaxRate | ApplicableTaxRate | pure | 0.19 | 2022-01-01 | 2022-12-31 | 2022 | FY | 20-F | 2023-03-10 | 0001193125-23-067105 |
| ifrs-full | Assets | Assets | GBP | 61.12B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | AuditorsRemuneration | AuditorsRemuneration | GBP | 23.30M | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | AuditorsRemunerationForAuditServices | AuditorsRemunerationForAuditServices | GBP | 20.90M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AuditorsRemunerationForOtherServices | AuditorsRemunerationForOtherServices | GBP | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 |
| ifrs-full | AuditorsRemunerationForTaxServices | AuditorsRemunerationForTaxServices | GBP | 100,000 | 2018-01-01 | 2018-12-31 | 2020 | FY | 20-F | 2021-03-12 | 0001193125-21-079417 |
| ifrs-full | AverageEffectiveTaxRate | AverageEffectiveTaxRate | pure | 0.15 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | AverageNumberOfEmployees | AverageNumberOfEmployees | numberOfEmployees | 68,307 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | BankOverdraftsClassifiedAsCashEquivalents | BankOverdraftsClassifiedAsCashEquivalents | GBP | 190.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | BasicEarningsLossPerShare | BasicEarningsLossPerShare | GBP/shares | 1.411 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | BasicEarningsLossPerShareFromContinuingOperations | BasicEarningsLossPerShareFromContinuingOperations | GBP/shares | 0.632 | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | BasicEarningsLossPerShareFromDiscontinuedOperations | BasicEarningsLossPerShareFromDiscontinuedOperations | GBP/shares | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | Borrowings | Borrowings | GBP | 14.45B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | BrandNames | BrandNames | GBP | 18.42B | 2021-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 | |
| ifrs-full | CapitalisationRateOfBorrowingCostsEligibleForCapitalisation | CapitalisationRateOfBorrowingCostsEligibleForCapitalisation | pure | 0.04 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | Cash | Cash | GBP | 761.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CashAndCashEquivalents | CashAndCashEquivalents | GBP | 3.40B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CashAndCashEquivalentsClassifiedAsPartOfDisposalGroupHeldForSale | CashAndCashEquivalentsClassifiedAsPartOfDisposalGroupHeldForSale | GBP | 0 | 2021-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 | |
| ifrs-full | CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup | CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup | GBP | 247.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition | CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition | GBP | 3.21B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CashAndCashEquivalentsRecognisedAsOfAcquisitionDate | CashAndCashEquivalentsRecognisedAsOfAcquisitionDate | GBP | 78.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CashEquivalents | CashEquivalents | GBP | 2.64B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities | CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities | GBP | -27.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CashFlowsFromUsedInFinancingActivities | CashFlowsFromUsedInFinancingActivities | GBP | -3.69B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CashFlowsFromUsedInFinancingActivitiesContinuingOperations | CashFlowsFromUsedInFinancingActivitiesContinuingOperations | GBP | -4.73B | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations | CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations | GBP | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings | CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings | GBP | 1.08B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CashFlowsFromUsedInInvestingActivities | CashFlowsFromUsedInInvestingActivities | GBP | -4.23B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CashFlowsFromUsedInInvestingActivitiesContinuingOperations | CashFlowsFromUsedInInvestingActivitiesContinuingOperations | GBP | -1.23B | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations | CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations | GBP | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | CashFlowsFromUsedInOperatingActivities | CashFlowsFromUsedInOperatingActivities | GBP | 7.74B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CashFlowsFromUsedInOperatingActivitiesContinuingOperations | CashFlowsFromUsedInOperatingActivitiesContinuingOperations | GBP | 6.55B | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations | CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations | GBP | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | CashFlowsFromUsedInOperations | CashFlowsFromUsedInOperations | GBP | 8.94B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities | CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities | GBP | 1.69B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CashOutflowForLeases | CashOutflowForLeases | GBP | 260.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CashTransferred | CashTransferred | GBP | 12.00M | 2019-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 | |
| ifrs-full | CommercialPapersIssued | CommercialPapersIssued | GBP | 1.08B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | ComprehensiveIncome | ComprehensiveIncome | GBP | 6.78B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ComprehensiveIncomeAttributableToNoncontrollingInterests | ComprehensiveIncomeAttributableToNoncontrollingInterests | GBP | 555.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ComprehensiveIncomeAttributableToOwnersOfParent | ComprehensiveIncomeAttributableToOwnersOfParent | GBP | 6.23B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ComprehensiveIncomeFromContinuingOperations | ComprehensiveIncomeFromContinuingOperations | GBP | -1.19B | 2022-01-01 | 2022-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | ComprehensiveIncomeFromDiscontinuedOperations | ComprehensiveIncomeFromDiscontinuedOperations | GBP | 356.00M | 2022-01-01 | 2022-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | ContingentConsiderationRecognisedAsOfAcquisitionDate | ContingentConsiderationRecognisedAsOfAcquisitionDate | GBP | 482.00M | 2022-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 | |
| ifrs-full | ContingentLiabilitiesRecognisedInBusinessCombination | ContingentLiabilitiesRecognisedInBusinessCombination | GBP | 6.73B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | ContingentRentsRecognisedAsExpenseClassifiedAsOperatingLease | ContingentRentsRecognisedAsExpenseClassifiedAsOperatingLease | GBP | 12.00M | 2018-01-01 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 |
| ifrs-full | ContractLiabilities | ContractLiabilities | GBP | 153.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | ContractualCommitmentsForAcquisitionOfIntangibleAssets | ContractualCommitmentsForAcquisitionOfIntangibleAssets | GBP | 17.05B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment | ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment | GBP | 764.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset | ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset | GBP | 283.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CostOfInventoriesRecognisedAsExpenseDuringPeriod | CostOfInventoriesRecognisedAsExpenseDuringPeriod | GBP | 6.36B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CostOfSales | CostOfSales | GBP | 9.02B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity | CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity | GBP | 24.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CurrentAssets | CurrentAssets | GBP | 17.51B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners | CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners | GBP | 113.00M | 2017-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 | |
| ifrs-full | CurrentDerivativeFinancialAssets | CurrentDerivativeFinancialAssets | GBP | 121.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CurrentDerivativeFinancialLiabilities | CurrentDerivativeFinancialLiabilities | GBP | 75.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading | CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading | GBP | 0 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 | |
| ifrs-full | CurrentLeaseLiabilities | CurrentLeaseLiabilities | GBP | 137.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CurrentLiabilities | CurrentLiabilities | GBP | 21.39B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax | CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax | GBP | 138.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CurrentRawMaterialsAndCurrentProductionSupplies | CurrentRawMaterialsAndCurrentProductionSupplies | GBP | 608.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CurrentServiceCostNetDefinedBenefitLiabilityAsset | CurrentServiceCostNetDefinedBenefitLiabilityAsset | GBP | 92.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CurrentTaxAssets | CurrentTaxAssets | GBP | 288.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods | CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods | GBP | 1.40B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes | CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes | GBP | 169.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | CurrentTaxLiabilities | CurrentTaxLiabilities | GBP | 498.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | CurrentTaxLiabilitiesNoncurrent | CurrentTaxLiabilitiesNoncurrent | GBP | 0 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 | |
| ifrs-full | CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity | CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity | GBP | 7.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DebtSecurities | DebtSecurities | GBP | 16.89B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions | DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions | GBP | -31.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DecreaseThroughClassifiedAsHeldForSaleRightofuseAssets | DecreaseThroughClassifiedAsHeldForSaleRightofuseAssets | GBP | 16.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DecreaseThroughTransferToLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSaleOtherProvisions | DecreaseThroughTransferToLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSaleOtherProvisions | GBP | 1.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DeferredIncome | DeferredIncome | GBP | 361.00M | 2020-12-31 | 2020 | FY | 20-F | 2021-03-12 | 0001193125-21-079417 | |
| ifrs-full | DeferredIncomeClassifiedAsNoncurrent | DeferredIncomeClassifiedAsNoncurrent | GBP | 21.00M | 2020-12-31 | 2020 | FY | 20-F | 2021-03-12 | 0001193125-21-079417 | |
| ifrs-full | DeferredTaxAssets | DeferredTaxAssets | GBP | 6.52B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | DeferredTaxExpenseIncome | DeferredTaxExpenseIncome | GBP | -283.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DeferredTaxExpenseIncomeRecognisedInProfitOrLoss | DeferredTaxExpenseIncomeRecognisedInProfitOrLoss | GBP | 396.00M | 2018-01-01 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 |
| ifrs-full | DeferredTaxLiabilities | DeferredTaxLiabilities | GBP | 291.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate | DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate | GBP | 316.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | DeferredTaxLiabilityAsset | DeferredTaxLiabilityAsset | GBP | -6.23B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity | DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity | GBP | 17.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DefinedBenefitObligationAtPresentValue | DefinedBenefitObligationAtPresentValue | GBP | 12.85B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | DepreciationAndAmortisationExpense | DepreciationAndAmortisationExpense | GBP | 2.31B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DepreciationPropertyPlantAndEquipment | DepreciationPropertyPlantAndEquipment | GBP | 850.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DepreciationRightofuseAssets | DepreciationRightofuseAssets | GBP | 206.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DerivativeFinancialAssets | DerivativeFinancialAssets | GBP | 156.00M | 2016-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 | |
| ifrs-full | DerivativeFinancialAssetsHeldForTrading | DerivativeFinancialAssetsHeldForTrading | GBP | 15.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | DerivativeFinancialLiabilities | DerivativeFinancialLiabilities | GBP | 21.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | DerivativeFinancialLiabilitiesHeldForTrading | DerivativeFinancialLiabilitiesHeldForTrading | GBP | 54.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | DescriptionOfDiscountRatesAppliedToCashFlowProjections | DescriptionOfDiscountRatesAppliedToCashFlowProjections | pure | 0.075 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | DilutedEarningsLossPerShare | DilutedEarningsLossPerShare | GBP/shares | 1.388 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DilutedEarningsLossPerShareFromContinuingOperations | DilutedEarningsLossPerShareFromContinuingOperations | GBP/shares | 0.622 | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | DilutedEarningsLossPerShareFromDiscontinuedOperations | DilutedEarningsLossPerShareFromDiscontinuedOperations | GBP/shares | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares | DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares | shares | 66.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DisposalsPropertyPlantAndEquipment | DisposalsPropertyPlantAndEquipment | GBP | 44.00M | 2019-01-01 | 2019-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 |
| ifrs-full | DisposalsRightofuseAssets | DisposalsRightofuseAssets | GBP | 45.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DistributionCosts | DistributionCosts | GBP | 202.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DividendsPaid | DividendsPaid | GBP | 2.56B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DividendsPaidClassifiedAsFinancingActivities | DividendsPaidClassifiedAsFinancingActivities | GBP | -3.91B | 2017-01-01 | 2017-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 |
| ifrs-full | DividendsPaidOrdinaryShares | DividendsPaidOrdinaryShares | GBP | 2.66B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DividendsPaidOrdinarySharesPerShare | DividendsPaidOrdinarySharesPerShare | GBP/shares | 0.66 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities | DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities | GBP | 2.56B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities | DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities | GBP | 412.00M | 2023-01-01 | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 |
| ifrs-full | DividendsReceivedClassifiedAsInvestingActivities | DividendsReceivedClassifiedAsInvestingActivities | GBP | 220.00M | 2023-01-01 | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 |
| ifrs-full | DividendsReceivedFromInvestmentsAccountedForUsingEquityMethodClassifiedAsInvestingActivities | DividendsReceivedFromInvestmentsAccountedForUsingEquityMethodClassifiedAsInvestingActivities | GBP | 67.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | DividendsRecognisedAsDistributionsToNoncontrollingInterests | DividendsRecognisedAsDistributionsToNoncontrollingInterests | GBP | 391.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | EffectOfExchangeRateChangesOnCashAndCashEquivalents | EffectOfExchangeRateChangesOnCashAndCashEquivalents | GBP | -19.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | EmployeeBenefitsExpense | EmployeeBenefitsExpense | GBP | 8.77B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | Equity | Equity | GBP | 15.96B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | EquityAndLiabilities | EquityAndLiabilities | GBP | 16.70B | 2017-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 | |
| ifrs-full | EquityAttributableToOwnersOfParent | EquityAttributableToOwnersOfParent | GBP | 16.38B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | EstimatedFinancialEffectOfContingentLiabilities | EstimatedFinancialEffectOfContingentLiabilities | GBP | 38.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | ExpenseDueToUnwindingOfDiscountOnProvisions | ExpenseDueToUnwindingOfDiscountOnProvisions | GBP | 29.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ExpenseFromSharebasedPaymentTransactionsWithEmployees | ExpenseFromSharebasedPaymentTransactionsWithEmployees | GBP | 390.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ExpenseOfRestructuringActivities | ExpenseOfRestructuringActivities | GBP | 109.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed | ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed | GBP | 2.00M | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed | ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed | GBP | 13.00M | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities | ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities | GBP | 15.00M | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | FinanceCosts | FinanceCosts | GBP | 701.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | FinanceIncome | FinanceIncome | GBP | 169.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | FinanceLeaseLiabilities | FinanceLeaseLiabilities | GBP | 68 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 | |
| ifrs-full | FinancialAssets | FinancialAssets | GBP | 11.07B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | FinancialAssetsAtFairValue | FinancialAssetsAtFairValue | GBP | 11.07B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities | FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities | GBP | 500,000 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 | |
| ifrs-full | FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount | FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount | GBP | 15.00M | 2018-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 | |
| ifrs-full | FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue | FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue | GBP | 0 | 2019-12-31 | 2019 | FY | 20-F | 2020-03-06 | 0001193125-20-065064 | |
| ifrs-full | FinancialLiabilities | FinancialLiabilities | GBP | 37.27B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | FinancialLiabilitiesAtFairValue | FinancialLiabilitiesAtFairValue | GBP | 37.26B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | FinishedGoods | FinishedGoods | GBP | 1.62B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | FutureFinanceChargeOnFinanceLease | FutureFinanceChargeOnFinanceLease | GBP | 16 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 | |
| ifrs-full | GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss | GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss | GBP | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | GainLossOnRemeasurementOfReimbursementRights | GainLossOnRemeasurementOfReimbursementRights | GBP | 1.19B | 2017-01-01 | 2017-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 |
| ifrs-full | GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset | GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset | GBP | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | GainsLossesOnCashFlowHedgesBeforeTax | GainsLossesOnCashFlowHedgesBeforeTax | GBP | -41.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | GainsLossesOnCashFlowHedgesNetOfTax | GainsLossesOnCashFlowHedgesNetOfTax | GBP | 513.00M | 2018-01-01 | 2018-12-31 | 2020 | FY | 20-F | 2021-03-12 | 0001193125-21-079417 |
| ifrs-full | GainsLossesOnChangeInFairValueOfDerivatives | GainsLossesOnChangeInFairValueOfDerivatives | GBP | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax | GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax | GBP | 15.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | GainsLossesOnChangeInValueOfTimeValueOfOptionsNetOfTax | GainsLossesOnChangeInValueOfTimeValueOfOptionsNetOfTax | GBP | 4.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | GainsLossesOnDisposalsOfInvestments | GainsLossesOnDisposalsOfInvestments | GBP | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | GainsLossesOnDisposalsOfNoncurrentAssets | GainsLossesOnDisposalsOfNoncurrentAssets | GBP | 6.00M | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | GainsLossesOnExchangeDifferencesOnTranslationBeforeTax | GainsLossesOnExchangeDifferencesOnTranslationBeforeTax | GBP | -22.00M | 2023-01-01 | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 |
| ifrs-full | GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss | GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss | GBP | 9.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue | GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue | GBP | 337.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeBeforeTax | GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeBeforeTax | GBP | -14.00M | 2017-01-01 | 2017-12-31 | 2019 | FY | 20-F | 2020-03-06 | 0001193125-20-065064 |
| ifrs-full | GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss | GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss | GBP | 892.00M | 2020-01-01 | 2020-12-31 | 2020 | FY | 20-F | 2021-03-12 | 0001193125-21-079417 |
| ifrs-full | GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations | GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations | GBP | 12.00M | 2022-01-01 | 2022-12-31 | 2022 | FY | 20-F | 2023-03-10 | 0001193125-23-067105 |
| ifrs-full | GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsBeforeTax | GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsBeforeTax | GBP | -14.00M | 2017-01-01 | 2017-12-31 | 2019 | FY | 20-F | 2020-03-06 | 0001193125-20-065064 |
| ifrs-full | GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementAssets | GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementAssets | GBP | 160.00M | 2020-01-01 | 2020-12-31 | 2020 | FY | 20-F | 2021-03-12 | 0001193125-21-079417 |
| ifrs-full | GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets | GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets | GBP | 1.27B | 2020-01-01 | 2020-12-31 | 2020 | FY | 20-F | 2021-03-12 | 0001193125-21-079417 |
| ifrs-full | GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments | GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments | GBP | -24.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | GainsOnDisposalsOfInvestments | GainsOnDisposalsOfInvestments | GBP | 37.00M | 2017-01-01 | 2017-12-31 | 2019 | FY | 20-F | 2020-03-06 | 0001193125-20-065064 |
| ifrs-full | Goodwill | Goodwill | GBP | 7.02B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | GoodwillRecognisedAsOfAcquisitionDate | GoodwillRecognisedAsOfAcquisitionDate | GBP | 315.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | GrossFinanceLeaseObligations | GrossFinanceLeaseObligations | GBP | 84 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 | |
| ifrs-full | GrossProfit | GrossProfit | GBP | 23.65B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | HedgingInstrumentAssets | HedgingInstrumentAssets | GBP | 130.00M | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 | |
| ifrs-full | HedgingInstrumentLiabilities | HedgingInstrumentLiabilities | GBP | 189.00M | 2019-12-31 | 2019 | FY | 20-F | 2020-03-06 | 0001193125-20-065064 | |
| ifrs-full | IdentifiableAssetsAcquiredLiabilitiesAssumed | IdentifiableAssetsAcquiredLiabilitiesAssumed | GBP | 1.70B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate | IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate | GBP | 1.97B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | ImpairmentLoss | ImpairmentLoss | GBP | 33.00M | 2023-01-01 | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 |
| ifrs-full | ImpairmentLossRecognisedInProfitOrLoss | ImpairmentLossRecognisedInProfitOrLoss | GBP | 1.11B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ImpairmentLossRecognisedInProfitOrLossGoodwill | ImpairmentLossRecognisedInProfitOrLossGoodwill | GBP | 4.00M | 2019-01-01 | 2019-12-31 | 2019 | FY | 20-F | 2020-03-06 | 0001193125-20-065064 |
| ifrs-full | ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill | ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill | GBP | 2.00M | 2020-01-01 | 2020-12-31 | 2022 | FY | 20-F | 2023-03-10 | 0001193125-23-067105 |
| ifrs-full | ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill | ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill | GBP | 888.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment | ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment | GBP | 193.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ImpairmentLossRecognisedInProfitOrLossRightofuseAssets | ImpairmentLossRecognisedInProfitOrLossRightofuseAssets | GBP | 17.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss | ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss | GBP | 4.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncomeFromContinuingOperationsAttributableToOwnersOfParent | IncomeFromContinuingOperationsAttributableToOwnersOfParent | GBP | 2.58B | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent | IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent | GBP | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | IncomeTaxesPaidClassifiedAsOperatingActivities | IncomeTaxesPaidClassifiedAsOperatingActivities | GBP | 1.20B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncomeTaxesPaidRefundClassifiedAsOperatingActivities | IncomeTaxesPaidRefundClassifiedAsOperatingActivities | GBP | 1.20B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncomeTaxExpenseContinuingOperations | IncomeTaxExpenseContinuingOperations | GBP | 1.11B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome | IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome | GBP | 2.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncomeTaxRelatingToFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome | IncomeTaxRelatingToFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome | GBP | -47.00M | 2017-01-01 | 2017-12-31 | 2019 | FY | 20-F | 2020-03-06 | 0001193125-20-065064 |
| ifrs-full | IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome | IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome | GBP | 20.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome | IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome | GBP | 33.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges | IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges | GBP | -177.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination | IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination | GBP | -581.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset | IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset | GBP | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset | IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset | GBP | 321.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions | IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions | GBP | 24.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset | IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset | GBP | -11.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseThroughDisposalOfSubsidiary | IncreaseDecreaseThroughDisposalOfSubsidiary | GBP | -2.00M | 2024-01-01 | 2024-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities | IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities | GBP | 2.45B | 2022-01-01 | 2022-12-31 | 2022 | FY | 20-F | 2023-03-10 | 0001193125-23-067105 |
| ifrs-full | IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities | IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities | GBP | 5.67B | 2022-01-01 | 2022-12-31 | 2022 | FY | 20-F | 2023-03-10 | 0001193125-23-067105 |
| ifrs-full | IncreaseDecreaseThroughForeignExchangeFinancialAssets | IncreaseDecreaseThroughForeignExchangeFinancialAssets | GBP | 3.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset | IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset | GBP | 79.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions | IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions | GBP | -83.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets | IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets | GBP | -17.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities | IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities | GBP | 301.00M | 2022-01-01 | 2022-12-31 | 2022 | FY | 20-F | 2023-03-10 | 0001193125-23-067105 |
| ifrs-full | IncreaseDecreaseThroughOtherDistributionsToOwners | IncreaseDecreaseThroughOtherDistributionsToOwners | GBP | 15.53B | 2022-01-01 | 2022-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | IncreaseDecreaseThroughSharebasedPaymentTransactions | IncreaseDecreaseThroughSharebasedPaymentTransactions | GBP | 374.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions | IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions | GBP | 28.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseThroughTransfersAndOtherChangesEquity | IncreaseDecreaseThroughTransfersAndOtherChangesEquity | GBP | -20.00M | 2022-01-01 | 2022-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 |
| ifrs-full | IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions | IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions | GBP | 7.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill | IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill | GBP | 48.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 |
| ifrs-full | IncreaseDecreaseThroughTransfersRightofuseAssets | IncreaseDecreaseThroughTransfersRightofuseAssets | GBP | 6.00M | 2023-01-01 | 2023-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | IntangibleAssetsOtherThanGoodwill | IntangibleAssetsOtherThanGoodwill | GBP | 16.75B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | InterestExpense | InterestExpense | GBP | 912.00M | 2022-01-01 | 2022-12-31 | 2022 | FY | 20-F | 2023-03-10 | 0001193125-23-067105 |
| ifrs-full | InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss | InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss | GBP | 612.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | InterestExpenseIncomeNetDefinedBenefitLiabilityAsset | InterestExpenseIncomeNetDefinedBenefitLiabilityAsset | GBP | -4.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | InterestExpenseOnFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLoss | InterestExpenseOnFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLoss | GBP | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 |
| ifrs-full | InterestExpenseOnLeaseLiabilities | InterestExpenseOnLeaseLiabilities | GBP | 46.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost | InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost | GBP | 56.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | InterestIncomeOnAvailableforsaleFinancialAssets | InterestIncomeOnAvailableforsaleFinancialAssets | GBP | 2.00M | 2017-01-01 | 2017-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 |
| ifrs-full | InterestIncomeOnCashAndCashEquivalents | InterestIncomeOnCashAndCashEquivalents | GBP | 60.00M | 2017-01-01 | 2017-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 |
| ifrs-full | InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss | InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss | GBP | 91.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | InterestIncomeOnLoansAndReceivables | InterestIncomeOnLoansAndReceivables | GBP | 1.00M | 2017-01-01 | 2017-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 |
| ifrs-full | InterestPaidClassifiedAsFinancingActivities | InterestPaidClassifiedAsFinancingActivities | GBP | 679.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | InterestPayable | InterestPayable | GBP | 52.00M | 2017-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 | |
| ifrs-full | InterestReceivable | InterestReceivable | GBP | 2.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | InterestReceivedClassifiedAsInvestingActivities | InterestReceivedClassifiedAsInvestingActivities | GBP | 154.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | Inventories | Inventories | GBP | 5.92B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | InventoryRecognisedAsOfAcquisitionDate | InventoryRecognisedAsOfAcquisitionDate | GBP | 60.00M | 2022-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 | |
| ifrs-full | InventoryWritedown2011 | InventoryWritedown2011 | GBP | 1.06B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | InvestmentAccountedForUsingEquityMethod | InvestmentAccountedForUsingEquityMethod | GBP | 89.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | InvestmentsInSubsidiariesJointVenturesAndAssociates | InvestmentsInSubsidiariesJointVenturesAndAssociates | GBP | 89.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | GBP | 2.13B | 2021-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 | |
| ifrs-full | IssuedCapital | IssuedCapital | GBP | 1.35B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | IssueOfEquity | IssueOfEquity | GBP | 15.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | KeyManagementPersonnelCompensation | KeyManagementPersonnelCompensation | GBP | 81.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | KeyManagementPersonnelCompensationPostemploymentBenefits | KeyManagementPersonnelCompensationPostemploymentBenefits | GBP | 2.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | KeyManagementPersonnelCompensationSharebasedPayment | KeyManagementPersonnelCompensationSharebasedPayment | GBP | 39.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | KeyManagementPersonnelCompensationShorttermEmployeeBenefits | KeyManagementPersonnelCompensationShorttermEmployeeBenefits | GBP | 34.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed | LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed | GBP | 2.00M | 2019-01-01 | 2019 | FY | 20-F | 2020-03-06 | 0001193125-20-065064 | |
| ifrs-full | LeaseLiabilities | LeaseLiabilities | GBP | 830.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | LegalProceedingsProvision | LegalProceedingsProvision | GBP | 210.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | Liabilities | Liabilities | GBP | 45.16B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | LiabilitiesArisingFromFinancingActivities | LiabilitiesArisingFromFinancingActivities | GBP | 20.89B | 2022-12-31 | 2022 | FY | 20-F | 2023-03-10 | 0001193125-23-067105 | |
| ifrs-full | LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale | LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale | GBP | 139.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | LiabilityAssetOfDefinedBenefitPlans | LiabilityAssetOfDefinedBenefitPlans | GBP | -229.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | LongtermBorrowings | LongtermBorrowings | GBP | 14.71B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | MaximumExposureToCreditRisk | MaximumExposureToCreditRisk | GBP | 12.57B | 2020-12-31 | 2020 | FY | 20-F | 2021-03-12 | 0001193125-21-079417 | |
| ifrs-full | MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease | MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease | GBP | 1.14B | 2018-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 | |
| ifrs-full | MinimumOperatingLeasePayments | MinimumOperatingLeasePayments | GBP | 188.00M | 2018-01-01 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 |
| ifrs-full | MiscellaneousOtherOperatingIncome | MiscellaneousOtherOperatingIncome | GBP | 237.00M | 2023-01-01 | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 |
| ifrs-full | NetAssetsLiabilities | NetAssetsLiabilities | GBP | 15.96B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NetDebt | NetDebt | GBP | 14.45B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination | NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination | GBP | 280.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | NominalAmountOfHedgingInstrument | NominalAmountOfHedgingInstrument | pure | 750.00M | 2021-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 | |
| ifrs-full | NoncontrollingInterests | NoncontrollingInterests | GBP | -421.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets | NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets | GBP | -83.00M | 2022-12-31 | 2022 | FY | 20-F | 2023-03-10 | 0001193125-23-067105 | |
| ifrs-full | NoncurrentAssets | NoncurrentAssets | GBP | 43.61B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale | NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale | GBP | 300.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners | NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners | GBP | 76.00M | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 | |
| ifrs-full | NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts | NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts | GBP | 33.97B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities | NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities | GBP | 121.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NoncurrentDerivativeFinancialAssets | NoncurrentDerivativeFinancialAssets | GBP | 0 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NoncurrentDerivativeFinancialLiabilities | NoncurrentDerivativeFinancialLiabilities | GBP | 67.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NoncurrentFinancialLiabilitiesAtFairValueThroughProfitOrLoss | NoncurrentFinancialLiabilitiesAtFairValueThroughProfitOrLoss | GBP | 5.38B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | GBP | 1.04B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NoncurrentLeaseLiabilities | NoncurrentLeaseLiabilities | GBP | 693.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NoncurrentLiabilities | NoncurrentLiabilities | GBP | 23.77B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NoncurrentProvisionsForEmployeeBenefits | NoncurrentProvisionsForEmployeeBenefits | GBP | 1.69B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NoncurrentRecognisedAssetsDefinedBenefitPlan | NoncurrentRecognisedAssetsDefinedBenefitPlan | GBP | 1.11B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | NumberOfSharesAuthorised | NumberOfSharesAuthorised | shares | 10.00B | 2018-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 | |
| ifrs-full | NumberOfSharesIssuedAndFullyPaid | NumberOfSharesIssuedAndFullyPaid | shares | 4.32B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | OnerousContractsProvision | OnerousContractsProvision | GBP | 6.00M | 2018-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 | |
| ifrs-full | OtherAdjustmentsToReconcileProfitLoss | OtherAdjustmentsToReconcileProfitLoss | GBP | -9.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities | OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities | GBP | 92.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities | OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities | GBP | 4.00M | 2020-01-01 | 2020-12-31 | 2020 | FY | 20-F | 2021-03-12 | 0001193125-21-079417 |
| ifrs-full | OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities | OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities | GBP | 189.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities | OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities | GBP | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 |
| ifrs-full | OtherComprehensiveIncome | OtherComprehensiveIncome | GBP | 493.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments | OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments | GBP | 215.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans | OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans | GBP | 133.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation | OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation | GBP | 213.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments | OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments | GBP | 215.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax | OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax | GBP | 216.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax | OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax | GBP | 277.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherCurrentFinancialAssets | OtherCurrentFinancialAssets | GBP | 42.00M | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 | |
| ifrs-full | OtherCurrentFinancialLiabilities | OtherCurrentFinancialLiabilities | GBP | 1.05B | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 | |
| ifrs-full | OtherCurrentPayables | OtherCurrentPayables | GBP | 438.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | OtherFinanceIncome | OtherFinanceIncome | GBP | 7.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherFinanceIncomeCost | OtherFinanceIncomeCost | GBP | -9.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherIncome | OtherIncome | GBP | -7.00M | 2018-01-01 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 |
| ifrs-full | OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates | OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates | GBP | -36.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 |
| ifrs-full | OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities | OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities | GBP | 46.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities | OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities | GBP | -11.00M | 2023-01-01 | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 |
| ifrs-full | OtherLongtermProvisions | OtherLongtermProvisions | GBP | 610.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | OtherMaterialNoncashItems | OtherMaterialNoncashItems | GBP | 18.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherNoncurrentAssets | OtherNoncurrentAssets | GBP | 2.15B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | OtherNoncurrentFinancialLiabilities | OtherNoncurrentFinancialLiabilities | GBP | 5.61B | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 | |
| ifrs-full | OtherNoncurrentLiabilities | OtherNoncurrentLiabilities | GBP | 1.02B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | OtherNoncurrentPayables | OtherNoncurrentPayables | GBP | 896.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | OtherNoncurrentReceivables | OtherNoncurrentReceivables | GBP | 80.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | OtherOperatingIncomeExpense | OtherOperatingIncomeExpense | GBP | 16.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherProvisions | OtherProvisions | GBP | 1.55B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | OtherReceivables | OtherReceivables | GBP | 1.15B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | OtherReserves | OtherReserves | GBP | 1.32B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | OtherShorttermProvisions | OtherShorttermProvisions | GBP | 938.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | OtherTangibleOrIntangibleAssetsTransferred | OtherTangibleOrIntangibleAssetsTransferred | GBP | 6.00M | 2019-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 | |
| ifrs-full | OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome | OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome | GBP | 33.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome | OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome | pure | 0.005 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ParValuePerShare | ParValuePerShare | GBP/shares | 0.25 | 2018-12-31 | 2019 | FY | 20-F | 2020-03-06 | 0001193125-20-065064 | |
| ifrs-full | PastServiceCostNetDefinedBenefitLiabilityAsset | PastServiceCostNetDefinedBenefitLiabilityAsset | GBP | 3.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | PaymentsFromChangesInOwnershipInterestsInSubsidiaries | PaymentsFromChangesInOwnershipInterestsInSubsidiaries | GBP | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 |
| ifrs-full | PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities | PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities | GBP | 28.00M | 2018-01-01 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 |
| ifrs-full | PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities | PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities | GBP | 241.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | PaymentsToAcquireOrRedeemEntitysShares | PaymentsToAcquireOrRedeemEntitysShares | GBP | 1.38B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents | PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents | GBP | 5.00M | 2022-01-01 | 2022-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | PostemploymentBenefitExpenseDefinedBenefitPlans | PostemploymentBenefitExpenseDefinedBenefitPlans | GBP | 170.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | PostemploymentBenefitExpenseDefinedContributionPlans | PostemploymentBenefitExpenseDefinedContributionPlans | GBP | 130.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | PostemploymentBenefitExpenseInProfitOrLoss | PostemploymentBenefitExpenseInProfitOrLoss | GBP | 300.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | Prepayments | Prepayments | GBP | 385.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | ProceedsFromContributionsOfNoncontrollingInterests | ProceedsFromContributionsOfNoncontrollingInterests | GBP | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations | ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations | GBP | 104.00M | 2019-01-01 | 2019-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 |
| ifrs-full | ProceedsFromIssuingShares | ProceedsFromIssuingShares | GBP | 15.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ProceedsFromNoncurrentBorrowings | ProceedsFromNoncurrentBorrowings | GBP | 1.98B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities | ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities | GBP | 115.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ProceedsFromSalesOfInterestsInAssociates | ProceedsFromSalesOfInterestsInAssociates | GBP | 3.00M | 2018-01-01 | 2018-12-31 | 2020 | FY | 20-F | 2021-03-12 | 0001193125-21-079417 |
| ifrs-full | ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod | ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod | GBP | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities | ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities | GBP | 24.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ProfitLoss | ProfitLoss | GBP | 6.29B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ProfitLossAttributableToNoncontrollingInterests | ProfitLossAttributableToNoncontrollingInterests | GBP | 573.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ProfitLossAttributableToOwnersOfParent | ProfitLossAttributableToOwnersOfParent | GBP | 5.72B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ProfitLossBeforeTax | ProfitLossBeforeTax | GBP | 7.40B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ProfitLossFromContinuingOperations | ProfitLossFromContinuingOperations | GBP | 2.95B | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests | ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests | GBP | 376.00M | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | ProfitLossFromDiscontinuedOperations | ProfitLossFromDiscontinuedOperations | GBP | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests | ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests | GBP | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 |
| ifrs-full | ProfitLossFromOperatingActivities | ProfitLossFromOperatingActivities | GBP | 7.93B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ProfitLossOfAcquiree | ProfitLossOfAcquiree | GBP | 0 | 2019-01-22 | 2019-12-31 | 2020 | FY | 20-F | 2021-03-12 | 0001193125-21-079417 |
| ifrs-full | ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments | ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments | GBP | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 |
| ifrs-full | PropertyPlantAndEquipment | PropertyPlantAndEquipment | GBP | 9.32B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate | PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate | GBP | 30.00M | 2022-12-31 | 2024 | FY | 20-F | 2025-03-03 | 0001131399-25-000007 | |
| ifrs-full | Provisions | Provisions | GBP | 0 | 2019-12-31 | 2019 | FY | 20-F | 2020-03-06 | 0001193125-20-065064 | |
| ifrs-full | ProvisionUsedOtherProvisions | ProvisionUsedOtherProvisions | GBP | 1.65B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities | PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities | GBP | 1.64B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod | PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod | GBP | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities | PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities | GBP | 1.35B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | PurchaseOfTreasuryShares | PurchaseOfTreasuryShares | GBP | 1.38B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | RatedCreditExposures | RatedCreditExposures | GBP | 5.14B | 2016-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 | |
| ifrs-full | RawMaterialsAndConsumablesUsed | RawMaterialsAndConsumablesUsed | GBP | 1.59B | 2023-01-01 | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 |
| ifrs-full | ReceivablesFromTaxesOtherThanIncomeTax | ReceivablesFromTaxesOtherThanIncomeTax | GBP | 511.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | ReclassificationAdjustmentsOnAvailableforsaleFinancialAssetsBeforeTax | ReclassificationAdjustmentsOnAvailableforsaleFinancialAssetsBeforeTax | GBP | 42.00M | 2017-01-01 | 2017-12-31 | 2019 | FY | 20-F | 2020-03-06 | 0001193125-20-065064 |
| ifrs-full | ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax | ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax | GBP | -36.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax | ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax | GBP | -36.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax | ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax | GBP | 12.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | RepaymentsOfBondsNotesAndDebentures | RepaymentsOfBondsNotesAndDebentures | GBP | 1.59B | 2022-01-01 | 2022-12-31 | 2022 | FY | 20-F | 2023-03-10 | 0001193125-23-067105 |
| ifrs-full | RepaymentsOfBorrowingsClassifiedAsFinancingActivities | RepaymentsOfBorrowingsClassifiedAsFinancingActivities | GBP | 2.50B | 2019-11-30 | 2020 | FY | 20-F | 2021-03-12 | 0001193125-21-079417 | |
| ifrs-full | RepaymentsOfCurrentBorrowings | RepaymentsOfCurrentBorrowings | GBP | 2.12B | 2023-01-01 | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 |
| ifrs-full | RepaymentsOfNoncurrentBorrowings | RepaymentsOfNoncurrentBorrowings | GBP | 1.40B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ResearchAndDevelopmentExpense | ResearchAndDevelopmentExpense | GBP | 7.53B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ReserveOfExchangeDifferencesOnTranslation | ReserveOfExchangeDifferencesOnTranslation | GBP | -894.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | RetainedEarnings | RetainedEarnings | GBP | 10.21B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset | ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset | GBP | 98.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | Revenue | Revenue | GBP | 32.67B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | RevenueAndOperatingIncome | RevenueAndOperatingIncome | GBP | 127.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods | RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods | GBP | 1.75B | 2023-01-01 | 2023-12-31 | 2023 | FY | 20-F | 2024-03-05 | 0001131399-24-000007 |
| ifrs-full | RevenueFromRenderingOfServices | RevenueFromRenderingOfServices | GBP | 7.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 |
| ifrs-full | RevenueFromRoyalties | RevenueFromRoyalties | GBP | 879.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | RevenueFromSaleOfGoods | RevenueFromSaleOfGoods | GBP | 32.67B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ReversalOfImpairmentLossRecognisedInProfitOrLoss | ReversalOfImpairmentLossRecognisedInProfitOrLoss | GBP | 16.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment | ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment | GBP | 33.00M | 2017-01-01 | 2017-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 |
| ifrs-full | ReversalOfImpairmentLossRecognisedInProfitOrLossRightofuseAssets | ReversalOfImpairmentLossRecognisedInProfitOrLossRightofuseAssets | GBP | 1.00M | 2024-01-01 | 2024-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ReversalOfInventoryWritedown | ReversalOfInventoryWritedown | GBP | 575.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ReversalOfProvisionsForCostOfRestructuring | ReversalOfProvisionsForCostOfRestructuring | GBP | 111.00M | 2022-01-01 | 2022-12-31 | 2022 | FY | 20-F | 2023-03-10 | 0001193125-23-067105 |
| ifrs-full | RightofuseAssets | RightofuseAssets | GBP | 726.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | RightofuseAssetsIncreaseDecreaseInRevaluationSurplus | RightofuseAssetsIncreaseDecreaseInRevaluationSurplus | GBP | -2.00M | 2020-01-01 | 2020-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 |
| ifrs-full | SellingGeneralAndAdministrativeExpense | SellingGeneralAndAdministrativeExpense | GBP | 9.09B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax | ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax | GBP | -77.00M | 2015-01-01 | 2015-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 |
| ifrs-full | ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod | ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod | GBP | 1.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | SharePremium | SharePremium | GBP | 3.50B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | ShorttermBorrowings | ShorttermBorrowings | GBP | 3.01B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | ShorttermDepositsClassifiedAsCashEquivalents | ShorttermDepositsClassifiedAsCashEquivalents | GBP | 2.84B | 2022-12-31 | 2022 | FY | 20-F | 2023-03-10 | 0001193125-23-067105 | |
| ifrs-full | ShorttermLegalProceedingsProvision | ShorttermLegalProceedingsProvision | GBP | 189.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | SocialSecurityContributions | SocialSecurityContributions | GBP | 865.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | SubleasePaymentsRecognisedAsExpense | SubleasePaymentsRecognisedAsExpense | GBP | 5.00M | 2018-01-01 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 |
| ifrs-full | TaxEffectFromChangeInTaxRate | TaxEffectFromChangeInTaxRate | GBP | 35.00M | 2017-01-01 | 2017-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 |
| ifrs-full | TaxEffectOfForeignTaxRates | TaxEffectOfForeignTaxRates | GBP | -20.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | TaxExpenseIncomeAtApplicableTaxRate | TaxExpenseIncomeAtApplicableTaxRate | GBP | 1.07B | 2022-01-01 | 2022-12-31 | 2022 | FY | 20-F | 2023-03-10 | 0001193125-23-067105 |
| ifrs-full | TaxRateEffectFromChangeInTaxRate | TaxRateEffectFromChangeInTaxRate | pure | 0.01 | 2017-01-01 | 2017-12-31 | 2017 | FY | 20-F/A | 2018-03-20 | 0001193125-18-088407 |
| ifrs-full | TaxRateEffectOfForeignTaxRates | TaxRateEffectOfForeignTaxRates | pure | -0.003 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | TaxRateEffectOfTaxLosses | TaxRateEffectOfTaxLosses | pure | 0.005 | 2018-01-01 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-15 | 0001193125-19-076716 |
| ifrs-full | TerminationBenefitsExpense | TerminationBenefitsExpense | GBP | 374.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | TradeAndOtherCurrentPayables | TradeAndOtherCurrentPayables | GBP | 15.38B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | TradeAndOtherCurrentReceivables | TradeAndOtherCurrentReceivables | GBP | 7.47B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | TradeAndOtherPayablesRecognisedAsOfAcquisitionDate | TradeAndOtherPayablesRecognisedAsOfAcquisitionDate | GBP | 39.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | TradeAndOtherPayablesToTradeSuppliers | TradeAndOtherPayablesToTradeSuppliers | GBP | 3.54B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | TradeAndOtherReceivables | TradeAndOtherReceivables | GBP | 7.47B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | TradeReceivables | TradeReceivables | GBP | 5.91B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | TreasuryShares | TreasuryShares | GBP | 3.95B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | UnusedProvisionReversedOtherProvisions | UnusedProvisionReversedOtherProvisions | GBP | 148.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised | UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised | GBP | 5.00M | 2021-12-31 | 2021 | FY | 20-F | 2022-03-08 | 0001193125-22-068957 | |
| ifrs-full | WagesAndSalaries | WagesAndSalaries | GBP | 6.84B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16 | WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16 | pure | 0.031 | 2019-01-01 | 2019 | FY | 20-F | 2020-03-06 | 0001193125-20-065064 | |
| ifrs-full | WeightedAverageShares | WeightedAverageShares | shares | 4.05B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |
| ifrs-full | WorkInProgress | WorkInProgress | GBP | 3.70B | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 | |
| ifrs-full | WritedownsReversalsOfPropertyPlantAndEquipment | WritedownsReversalsOfPropertyPlantAndEquipment | GBP | 3.00M | 2020-01-01 | 2020-12-31 | 2020 | FY | 20-F | 2021-03-12 | 0001193125-21-079417 |
| srt | CommercialPaperAverageRatePaid | CommercialPaperAverageRatePaid | pure | 0.038 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-03-06 | 0001131399-26-000004 |